Company profile
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ: DMAA · Financial Services · Shell Companies
#1 of 1,011 Financial Services companies by revenue
EA Score
——FH 54DQ —GM —SS 28
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, return on assets · ↓ workforce scale, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$5.9M
Employees
2
as of 2026-09-13
Market cap
$262.2M
as of 2026-09-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income$5.9M$5.9M2025
Operating income-$2.8M-$2.8M2025
Total assets$239.9M$239.9M2025
Liabilities$7.3M$7.3M2025
Equity-$7.3M-$7.3M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Drugs Made In America Acquisition Corp. Ordinary Shares’s financial profile?
Drugs Made In America Acquisition Corp. Ordinary Shares earned $5.9M in FY2025 net income.
Peers · Financial Services
Cantor Equity Partners V, Inc. Class A Ordinary Shares——ProCap Acquisition Corp——Hall Chadwick Acquisition Corp.——FACT II Acquisition Corp——Virginia National Bankshares Corporation——Irenic Acquisition Corp.——Neighbors
Broward →Key facts
CEORoger Bendelac
SectorFinancial Services
IndustryShell Companies
HeadquartersFort Lauderdale, FL
ExchangeNASDAQ: DMAA
Employees2
IPO date2025-01-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.